{'fraction_non_alphanumeric': 0.031450577663671375, 'fraction_numerical': 0.023106546854942234, 'mean_word_length': 5.066147859922179, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Non-gastrointestinal malt lymphomas: a study of 10 cases and comparison with 27 patients with gastrointestinal MALT lymphoma.

the CD79b-positive group we observed more frequently both atypical morphology (p<0.01) and strong surface immunoglobulin density (p<0.04). On the other hand, no difference was found with respect to clinical stage, absolute peripheral blood lymphocytosis, pattern of bone marrow infiltration, FMC7 expression, or CD20/CD22 ABC values. The relatively discordant data reported in the literature on the expression of CD79b antigen by neoplastic B-cells in CLL could be due to the different antibodies (SN8 or CB3-1 clones) or fluorocromes (PE or FITC) used as well as to the heterogeneous clinical, immunologic and laboratory features of patients evaluated. In this setting, we would like to stress that in our hands the substitution of CD79b for CD22 in the practical approach to the diagnosis of leukemic B-cell CLDs has improved our diagnostic ability from 90% to 92% of cases (data not shown). In other words, 8% of CLDs remained difficult to categorize from our immunologic point of view. Thus, further studies on larger numbers of patients with well-defined immunologic characteristics, and testing for both SN8 and CB3-1 clones (conjugated with several fluorocromes) need to be performed in order to obtain more useful informations on the significance of CD79b expression in B-CLL (and in other CLDs). Whether this information will be useful to classify CLDs better and to refine prognostic assessment remains to be established.